Navigation Links
Drug combination promotes weight loss in polycystic ovary syndrome
Date:6/17/2013

SAN FRANCISCO-- Women with polycystic ovary syndrome, or PCOS, lost significantly more weight when they took two drugs that are traditionally used to treat diabetes, rather than either drug alone, a study from Slovenia demonstrates. The results will be presented Monday at The Endocrine Society's 95th Annual Meeting in San Francisco.

PCOS is the leading cause of infertility among women. In the United States, the disorder affects approximately 5 million women, according to the U.S. Department of Health and Human Services Office of Women's Health. This translates to 1 in 10 to 20 women, overall, who are affected. The disease probably is genetic, although the exact causes are still unknown.

In PCOS, the ovaries produce excessive amounts of male sex hormones, or androgens. The name of the disease derives from small cysts that form on the ovaries, which do not produce enough of the hormone that triggers ovulation. When this occurs, the ovarian follicles, which have filled with fluid in preparation for ovulation, remain as cysts when ovulation fails to take place. In addition to infertility, symptoms include excessive hair growth in areas that usually are relatively hairless; obesity; menstrual irregularity; thinning or balding hair on the scalp; prediabetes or diabetes; and anxiety or depression. Weight loss in these women leads to higher chances of conception, improved pregnancy outcomes and improved metabolic profile.

Treatment varies depending upon the severity of the disease, and includes lifestyle modifications and drug therapy. Some of the same medications that are used to treat diabetes also improve PCOS symptoms. One of these medications, metformin, works by regulating the hormone insulin and by suppressing androgen activity, which, in turn, helps control blood-sugar levels and has beneficial effects on ovarian function. The problem with metformin, however, is that it does not always aid with weight loss.

Because of this, investigators examined different drug combinations to see which ones caused the most weight loss. In addition to metformin, they administered another diabetes medication called liraglutide, both alone and in combination with metformin, to determine which approach led to the greatest amount of weight loss.

They found that patients who took the combined drugs lost 6.5 kilograms (kg), or about 14 pounds, on average, compared to about 4 kg, or almost 9 pounds, on liraglutide alone, and 1 kg, or about 2 pounds, on metformin alone. Furthermore, 22 percent of participants on the combined treatment lost a significant amount of weight, defined as 5 percent or more of their body weight, compared to 16 percent of those on liraglutide. No one in the metformin group achieved this amount of weight loss. In terms of body-mass index and waist circumference, the combined-treatment group saw greater improvements than either of the single-medication groups. For both of these measurements, liraglutide alone outperformed metformin alone.

"The effect of metformin on weight reduction in polycystic ovary syndrome is often unsatisfactory," said study author Mojca Jensterle Sever, MD, PhD, who served as lead author with Andrej Janez, MD, PhD, a fellow consultant at the University Medical Center in Ljubljana, Slovenia. "Short-term combined treatment with liraglutide and metformin appears better than either metformin or liraglutide alone on weight loss and decrease in waist circumference in obese women with PCOS who had been previously poor responders regarding weight reduction on metformin alone."

The main side effect was nausea, which occurred more often with liraglutide than with metformin. The nausea did improve with time, however, and was not associated with weight loss.

Study participants comprised 36 women with PCOS who had lost less than 5 percent of their body weight on a six-month course of metformin preceding the study. Their average age was 31 years. Investigators randomly assigned them to one of three treatment groups for the 12-week study, including metformin alone, liraglutide alone, and both medications.

The University Medical Center Ljubljana, Slovenia, funded the study.


'/>"/>

Contact: Jenni Glenn Gingery
jgingery@endocrine.org
301-941-0240
The Endocrine Society
Source:Eurekalert

Related medicine news :

1. Twelve Minutes’ Exercise Per Week ‘Enough to Stay Fit’ in Combination with PhenObestin 37.5 to Burn Fat
2. Combination of drugs produces dramatic tumor responses in advanced melanoma patients
3. Melanoma Patients Receive Promising News Regarding Cancer Immunotherapy Combination Treatment
4. Underactive Thyroid and Heart Failure a Bad Combination: Study
5. Learn How to Incorporate Ayruveda into Yoga Practices, Discover Dosha Combinations, and How to Live in Balance this Saturday, May 18th at The YogaSoul Center
6. Added benefit of saxagliptin/metformin combination is not proven
7. New drug combination therapy developed to treat leukemia
8. Some patients with incurable tumors and BRCA mutations respond to new 2-drug combination
9. Different drug combinations work best for prevention versus treatment of colorectal tumors
10. Combination therapy provides similar clinical benefit as single drug treatment in MS
11. Comparing combination therapies for advanced head and neck cancer shows no improvement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... April 25, 2017 , ... As Spring reignites vigilance ... research related to Zika virus during pregnancy, as well as other prenatal exposures ... science. , The Teratology Society is an international and multidisciplinary ...
(Date:4/25/2017)... ... ... Buyers and sellers in the thriving multi-billion dollar cannabis marketplace – from ... be heartened by the industry’s current surge. But another thing that unifies them is ... At last they can simply, safely and effectively end their aroma anguish thanks to ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... of predictive analytics to its patient care management module. Using this new feature, ... a patient has been initiated on continuous positive airway pressure (CPAP), oral, or ...
(Date:4/25/2017)... , ... April 25, 2017 , ... There is no ... Hospital, according to a special report in the May issue of Consumer Reports focused ... highest quality ranking for results achieved during and after coronary bypass and aortic valve ...
(Date:4/25/2017)... ... April 25, 2017 , ... Amendia, Inc., designer, ... its strategic partnership with and platinum sponsorship of Global Spine Outreach (“GSO”), a ... effective management of complex spine deformity cases, particularly in children. , GSO’s focus ...
Breaking Medicine News(10 mins):
(Date:4/21/2017)... April 21, 2017 Halo Labs announces the ... particle analysis system called the Horizon at PEGS 2017 ... The new system analyzes sub visible particulate matter in ... particle screening as early as candidate selection and pre-formulation. ... biopharma contract research organization Elion Labs for ...
(Date:4/20/2017)... 20, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... announced that it will be participating in the Deutsche ... InterContinental Hotel in Boston, Massachusetts ... at 11:20 a.m. Eastern Time. A live ... Biomet,s Investor Relations website at http://investor.zimmerbiomet.com .  The ...
(Date:4/20/2017)... Research and Markets has announced the addition of the ... Market and Increasing Usage of Complex Biologics during the Forecast Period" ... ... 20 Billion in 2015 to around USD 26 Billion by 2020. ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ...
Breaking Medicine Technology: